<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">It was reported that multiple derivatives of non-immunosuppressive CsA were effective in inhibiting hCoV-229E replication, indicating that they could be a candidate drug for the treatment of CoV infection in humans [
 <xref rid="bb0020" ref-type="bibr">4</xref>,
 <xref rid="bb0185" ref-type="bibr">36</xref>]. CsA and its derivatives interrupt the interaction between CyPA and CaN proteins [
 <xref rid="bb0195" ref-type="bibr">38</xref>]. The study also found that in cells, CyPA inhibitors - alisporivir can inhibit the replication of MERS and SARS CoVs, and in cell-based infection models, ribavirin further enhances alisporivir's antiviral effect [
 <xref rid="bb0200" ref-type="bibr">39</xref>].
</p>
